Papers
4
Total Citations
108
H-Index
4
About
C. Lanchon is a leading urologic surgeon and researcher whose work focuses on advancing nephron-sparing surgery and minimally invasive techniques for kidney and prostate cancers. Their major contributions center on optimizing partial nephrectomy outcomes, particularly through comparative studies of surgical approaches. In a landmark 2016 study (42 citations), Lanchon compared partial nephrectomy versus ablative therapy for imperative renal tumor treatment, providing crucial guidance for high-risk patients. Their most impactful work includes the EMERALD randomized controlled trial (2021, 32 citations), which demonstrated that superselective ischemia in robotic partial nephrectomy does not improve long-term renal function over standard renal artery clamping—a finding that challenges established practices and influences surgical decision-making. Lanchon further advanced the field through prospective matched-pair analyses (2018, 25 citations) evaluating super-selective robot-assisted partial nephrectomy using near-infrared fluorescence versus early-unclamping techniques. Additionally, their innovative preclinical work on augmented reality using transurethral ultrasound for laparoscopic radical prostatectomy (2016, 9 citations) showcases their commitment to integrating cutting-edge technology into surgical practice. With over 100 total citations, Lanchon’s rigorous clinical trials and comparative effectiveness research continue to shape evidence-based urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4